Vanessa Vilani Addad, Lilian Monteiro Pereira Palma, Maria Helena Vaisbich, Abner Mácola Pacheco Barbosa, Naila Camila da Rocha, Marilia Mastrocolla de Almeida Cardoso, Juliana Tereza Coneglian de Almeida, Monica Ap de Paula de Sordi, Juliana Machado-Rugolo, Lucas Frederico Arantes, Luis Gustavo Modelli de Andrade
BACKGROUND: Thrombotic Microangiopathy (TMA) is a syndrome characterized by the presence of anemia, thrombocytopenia and organ damage and has multiple etiologies. The primary aim is to develop an algorithm to classify TMA (TMA-INSIGHT score). METHODS: This was a single-center retrospective cohort study including hospitalized patients with TMA at a single center. We included all consecutive patients diagnosed with TMA between 2012 and 2021. TMA was defined based on the presence of anemia (hemoglobin level < 10 g/dL) and thrombocytopenia (platelet count < 150,000/µL), signs of hemolysis, and organ damage...
November 22, 2023: Thrombosis Journal
Wenlin Xu, Jiana Chen, Shuyi Wu, Nianxu Huang, Xia Chen, Wang Zhang, Wei Hu, Jun Su, Hengfen Dai, Ping Gu, Xiaohong Huang, Xiaoming Du, Ruijuan Li, Qiaowei Zheng, Xiangsheng Lin, Yanxia Zhang, Lang Zou, Yuxin Liu, Min Zhang, Xiumei Liu, Zhu Zhu, Jinhua Zhang
BACKGROUND: There are limited data about the clinical benefits and harm of direct oral anticoagulants (DOACs) in stroke prevention in patients with atrial fibrillation (AF) complicated with anemia or thrombocytopenia. METHODS: This is a multi-center retrospective cohort study involving 5469 AF patients from 15 hospitals in China. Patients were divided into three groups according to hemoglobin and platelet levels: Group 1 (hemoglobin male ≥ 130 g/L; female ≥ 120 g/L and platelet ≥ 100 × 109 /L), Group 2 (hemoglobin male < 130 g/L; female < 120 g/L or platelet < 100 × 109 /L), and Group 3 (hemoglobin male < 130 g/L; female < 120 g/L and platelet < 100 × 109 /L)...
November 21, 2023: Thrombosis Journal
Wojciech Lizurej, Łukasz Mazurkiewicz, Michał Kowalski, Sylwia Szydłowska, Michał Wyrzykowski, Krzysztof Lewandowski
Mixed phenotype acute leukaemia (MPAL) is associated with worse overall survival, compared with other acute leukaemias in adults. Lack of clear treatment guidelines makes the therapy challenging. ALL-like induction and consolidation treatment followed by allo-HSCT is the preferred first-line treatment. We present a case of a 36-year-old woman diagnosed with MPAL (EGIL Myelo/B) with KMT2A rearrangement, treated with the PALG-ALL-7 (including PEG-asparaginase) protocol. On day 25 after the induction therapy initiation, numbness of limbs and dizziness were observed...
November 16, 2023: Thrombosis Journal
Hayaa M Alhuthali, Eman F Ataya, Alaa Alsalmi, Triq E Elmissbah, Khalaf F Alsharif, Hind A Alzahrani, Ahad Amer Alsaiari, Mamdouh Allahyani, Amal F Gharib, Husam Qanash, Heba M Elmasry, Doha Elsayed Hassanein
BACKGROUND: Alpha-thalassemia (α-thalassemia) is one of the most common monogenic diseases in Saudi Arabia and is associated with significant morbidity. Premarital testing programs in Saudi Arabia reduce the burden of hemoglobinopathy disorders, and ongoing monitoring is required. We aimed to explore the molecular nature of α-globin genes and identify the most common genotypes and regions with a high risk of α-thalassemia in Saudi Arabia. METHODS: This retrospective study was conducted between January 2021 and December 2022...
November 10, 2023: Thrombosis Journal
Yu-Zhou Chang, Hao-Yu Zhu, Yu-Qi Song, Xu Tong, Xiao-Qing Li, Yi-Long Wang, Ke-Hui Dong, Chu-Han Jiang, Yu-Peng Zhang, Da-Peng Mo
OBJECTIVES: Cerebral venous sinus thrombosis (CVST) can cause sinus obstruction and stenosis, with potentially fatal consequences. High-resolution magnetic resonance imaging (HRMRI) can diagnose CVST qualitatively, although quantitative screening methods are lacking for patients refractory to anticoagulation therapy and who may benefit from endovascular treatment (EVT). Thus, in this study, we used radiomic features (RFs) extracted from HRMRI to build machine learning models to predict response to drug therapy and determine the appropriateness of EVT...
November 10, 2023: Thrombosis Journal
Ning Zhu, Shanhong Lin, Chao Cao
Acute pulmonary embolism (APE) is a potentially fatal disease. Early risk stratification is essential to determining appropriate treatment. We aimed to investigate the predictive value of the Naples Prognostic Score (NPS) for 30-day all-cause mortality in patients with APE. In this retrospective analysis, 325 hospitalized patients with APE were divided into Groups 0 (n = 131), 1 (n = 153), and 2 (n = 41) according to the NPS. The primary outcome event was all-cause mortality during 30 days of follow-up from the day of admission...
November 6, 2023: Thrombosis Journal
Chiara Schiavi, Luca Marri, Simone Negrini
Systemic lupus erythematosus (SLE) patients have an increased risk of cardiovascular disease and thrombotic events, and the presence of antiphospholipid antibodies further raises the risk of these complications. Here we report a case of a patient with SLE and triple positivity for antiphospholipid antibodies who developed a popliteal artery thrombosis in the context of a severe hyperhomocysteinemia after the introduction of methotrexate (MTX) treatment. MTX is one of the most prescribed medications for a wide spectrum of autoimmune diseases, including SLE...
November 3, 2023: Thrombosis Journal
Toshiaki Iba, Tomoki Tanigawa, Hideo Wada, Jerrold H Levy
BACKGROUND: Disseminated intravascular coagulation (DIC) is a common and critical complication in sepsis. Antithrombin activity, which is considered a biomarker for disease severity, was measured in septic DIC treated with antithrombin concentrates in this study. METHODS: We conducted a retrospective analysis of post-marketing survey data that included 1,800 patients with sepsis-associated DIC and antithrombin activity of 70% or less who were treated with antithrombin concentrates...
November 2, 2023: Thrombosis Journal
Camille Lineberry, Dimitri Alexis, Ambika Mukhi, Kevin Duh, Mathew Tharakan, James A Vosswinkel, Randeep S Jawa
BACKGROUND: Venous thromboembolic events (VTE) are a significant cause of morbidity and mortality following traumatic injury. We examined demographic characteristics, chemoprophylaxis, and outcomes of VTE patients with blunt trauma requiring hospitalization. METHODS: A retrospective review of adult blunt trauma hospitalizations with and without VTE between 2012 and 2019 was conducted. Deaths in the emergency department were excluded. Univariate and multivariable analyses, including machine learning classification algorithms for VTE, were performed...
October 27, 2023: Thrombosis Journal
Farooq Akram, Bingwen Eugene Fan, Chuen Wen Tan, Wey Chyi Teoh, Paolo Prandoni, Eng Soo Yap
Current clinical practice guidelines lack explicit guidance on the indications and appropriate timing of venous ultrasound (US) in lower extremity deep vein thrombosis (DVT) follow-up. Moreover, abnormal findings reported on venous US in DVT follow-up or suspected recurrent DVT may be difficult for clinicians to interpret, which carries risk of harm from inappropriate use of anti- coagulation and increased healthcare resource utilization. Due to the above factors, over-use of ultrasound in diagnosis and follow-up of lower extremity DVT has been reported in western health systems...
October 26, 2023: Thrombosis Journal
Shuping Wang, Yongxiang Wang, Ming Bai, Yu Peng, Dan Zhou, Peng Lei, Binpeng Zhou, Piyi Zhang, Zheng Zhang
BACKGROUND: Previous cohort studies have shown that exogenous sex hormone use, such as testosterone replacement therapy and oestrogen-containing contraceptives, can increase the risk of venous thromboembolism (VTE). However, the relationship between endogenous sex hormone levels and VTE remains unclear. The goal of the present study was to explore the causal roles of endogenous sex hormones, including hormone-binding globulin (SHBG), bioactive testosterone (BT), and total testosterone (TT), in VTE and its two subgroups, deep vein thrombosis (DVT) and pulmonary embolism (PE)...
October 25, 2023: Thrombosis Journal
Minh Tam Nguyen, Thanh Tung Nguyen, Duy Bac Nguyen, Thi Mai Nguyen, Kim Ngan Nguyen, Van Nhat Minh Ngo, Van Dieu Nguyen, Ngoc Anh Tran, Mulias Lian, Arnold S C Tan, Samuel S Chong, Tien Truong Dang
BACKGROUND: Hemophilia A (HEMA) is an X-linked bleeding disorder caused by reduced/absent coagulation factor VIII expression, as a result of pathogenic variants in the F8 gene. Preimplantation prevention of HEMA should ideally include direct pathogenic F8 variant detection, complemented by linkage analysis of flanking markers to identify the high-risk F8 allele. Linkage analysis is particularly indispensable when the pathogenic variant cannot be detected directly or identified. This study evaluated the suitability of a panel of F8 intragenic and extragenic short tandem repeat markers for standalone linkage-based preimplantation genetic testing for monogenic disorder (PGT-M) of the Inv22 pathogenic variant, an almost 600 kb paracentric inversion responsible for almost half of all severe HEMA globally, for which direct detection is challenging...
October 20, 2023: Thrombosis Journal
Pengcheng Xu, Shouqing Han, Ming Hou, Yajing Zhao, Miao Xu
BACKGROUND: Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disease characterized by increased platelet destruction and impaired thrombopoiesis. The changes in platelet indices depend on the morphology and volume of platelets. Serum lipids have been found to affect platelet formation and activity in certain diseases, thus inducing the corresponding variation of platelet indices. METHODS: Mendelian randomization (MR) analysis was performed based on databases...
October 13, 2023: Thrombosis Journal
Zhencan Lin, Hao Sun, Deng Li, Zhiqing Cai, Zhencheng Huang, Fangzhou Liu, Meiyi Chen, Yimin Wang, Jie Xu, Ruofan Ma
INTRODUCTION: Deep venous thrombosis (DVT) prediction after total hip and knee arthroplasty remains challenging. Early diagnosis and treatment of DVT are crucial. This research aimed to develop a nomogram for early DVT prediction. METHODS: A total of 317 patients undergoing primary total hip and knee arthroplasty in Sun Yat-sen Memorial Hospital were enrolled between May 2020 and September 2022. Data from May 2020 to February 2022 were used as the development datasets to build the nomogram model (n = 238)...
October 12, 2023: Thrombosis Journal
Xiaozhe Li, Xiuli Sun, Baijun Fang, Yun Leng, Fangfang Sun, Yaomei Wang, Qing Wang, Jie Jin, Min Yang, Bing Xu, Zhihong Fang, Lijuan Chen, Zhi Chen, Qimei Yang, Kejie Zhang, Yinhai Ye, Hui Geng, Zhiqiang Sun, Dan Hao, Hongming Huang, Xiaotao Wang, Hongmei Jing, Lan Ma, Xueyi Pan, Wenming Chen, Juan Li
BACKGROUND: Individuals with multiple myeloma (MM) receiving immunomodulatory drugs (IMiDs) are at risk of developing venous thromboembolism (VTE), a serious complication. There is no established clinical model for predicting VTE in the Chinese population. We develop a new risk assessment model (RAM) for IMiD-associated VTE in Chinese MM patients. METHODS: We retrospectively selected 1334 consecutive MM patients receiving IMiDs from 16 medical centers in China and classified them randomly into the derivation and validation cohorts...
October 4, 2023: Thrombosis Journal
Joseph W Jackson, Colin Longstaff, Samuel A Woodle, William C Chang, Mikhail V Ovanesov
BACKGROUND: Fluorogenic thrombin generation (TG) is a global hemostasis assay that provides an overall representation of hemostasis potential. However, the accurate detection of thrombin activity in plasma may be affected by artifacts inherent to the assay-associated fluorogenic substrate. The significance of the fluorogenic artifacts or their corrections has not been studied in hemophilia treatment applications. METHODS: We sought to investigate TG in hemophilia plasma samples under typical and worst-case fluorogenic artifact conditions and assess the performance of artifact correction algorithms...
October 4, 2023: Thrombosis Journal
Lei Li, Jian Li, Xi Wu, Wenman Wu, Qiulan Ding, Baohua Qian, Xuefeng Wang
BACKGROUND: R189W and K193del of protein C (PC) were hotspot mutations in Chinese population with venous thromboembolism (VTE), but almost two-thirds of patients with above mutations coexisting with other genetically or aquiredly prothrombotic risk factors. The aim of this study is to clarify the independent contributions of R189W or K193del to VTE risk. METHODS: 490 unrelated patients with a personal history of VTE and 410 healthy participants were enrolled in this study...
October 3, 2023: Thrombosis Journal
Sandra Jonmarker, Jacob Litorell, Felix Alarcon, Kais Al-Abani, Sofia Björkman, Maria Farm, Jonathan Grip, Mårten Söderberg, Jacob Hollenberg, Rebecka Rubenson Wahlin, Thomas Kander, Liivi Rimling, Johan Mårtensson, Eva Joelsson-Alm, Martin Dahlberg, Maria Cronhjort
BACKGROUND: Patients with critical COVID-19 have a high risk of thromboembolism, but intensified thromboprophylaxis has not been proven beneficial. The activity of low-molecular-weight heparins can be monitored by measuring anti-Factor Xa. We aimed to study the association between anti-Factor Xa values and death, thromboembolism, and bleeding in patients with critical COVID-19. METHOD: This retrospective cohort study included adult patients with critical COVID-19 admitted to an intensive care unit at three Swedish hospitals between March 2020 and May 2021 with at least one valid peak and/or trough anti-Factor Xa value...
October 2, 2023: Thrombosis Journal
Shouqing Han, Hui Lu, Yafei Yu, Xinguang Liu, Fangmiao Jing, Liang Wang, Yajing Zhao, Ming Hou
BACKGROUND: Immune thrombocytopenia (ITP) is an autoimmune hemorrhagic disease characterized by low platelet count and bleeding manifestations. However, some patients also suffered from atherosclerosis or even infarction. Apart from activated platelets, lipid metabolism takes a large part in the formation of atherosclerosis and metabolic syndrome. The lipid metabolic state in ITP patients is still unknown. METHODS: We retrospectively reviewed 302 hospitalized ITP patients in our cohort, comparing their blood lipids, bleeding symptoms, metabolic diseases and treatment responses...
October 2, 2023: Thrombosis Journal
Antoine Barocas, Philippe Savard, Audrey Carlo, Thomas Lecompte, Emmanuel de Maistre
BACKGROUND: In case of heparin-induced thrombocytopenia (HIT), the switch to a non-heparin anticoagulant is mandatory, at a therapeutic dose. Such a treatment has limitations though, especially for patients with renal and/or hepatic failure. Candidate laboratory tests could detect the more coagulable HIT patients, for whom therapeutic anticoagulation would be the more justified. PATIENTS AND METHODS: This was a monocentre observational prospective study in which 111 patients with suspected HIT were included...
September 19, 2023: Thrombosis Journal
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read

Save your favorite articles in one place with a free QxMD account.


Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.